Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

4.5%

1 terminated out of 22 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results75% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (7)
P 1 (2)
P 2 (4)
P 3 (1)

Trial Status

Recruiting10
Not Yet Recruiting6
Completed3
Terminated1
Unknown1
Active Not Recruiting1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT05006131RecruitingPrimary

Pancreatic Cancer Screening for At-risk Individuals

NCT07529626Not Yet Recruiting

Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer

NCT06803771Not ApplicableRecruiting

Surveillance of Pancreatic Health After Diabetes Diagnosis

NCT07478185Not ApplicableNot Yet RecruitingPrimary

Prehab for Pancreatic Cancer Surgery

NCT07436741Phase 3Not Yet RecruitingPrimary

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT03977233Phase 2Recruiting

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

NCT06717295Recruiting

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

NCT06388967Recruiting

Pancreatic Cancer Detection Consortium

NCT07277452Phase 2Not Yet RecruitingPrimary

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

NCT06584227Phase 2RecruitingPrimary

Adebrelimab and Chidamide for Pancreatic Cancer

NCT03854110Phase 1Active Not RecruitingPrimary

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

NCT06852014Not ApplicableRecruitingPrimary

Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study

NCT01834235Phase 1TerminatedPrimary

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

NCT06822413Recruiting

Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis

NCT06938503Phase 2Not Yet RecruitingPrimary

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

NCT06800469Not ApplicableRecruitingPrimary

Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer

NCT06760741Not Yet RecruitingPrimary

PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention

NCT06747481RecruitingPrimary

Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer

NCT04002128Not ApplicableCompleted

Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery

NCT04136522Not ApplicableUnknownPrimary

Usefulness of the Artery First Approach in Pancreatic Cancer Surgery

Scroll to load more

Research Network

Activity Timeline